報價延遲最少15分鐘:2024/05/15 21:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.6 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.08/-5.21
|
|
企業價值
706.11M
|
| 資產負債 |
|
每股賬面淨值
3.23
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
17.16M
|
|
每股收益
0.55
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/15 21:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |